MAP3K7 anticorps (AA 101-400) (FITC)

N° du produit ABIN7160055

L’anticorps anti-MAP3K7 Polyclonal Lapin est utilisé pour la détection de MAP3K7 dans des échantillons de Humain.

Aperçu rapide pour MAP3K7 anticorps (AA 101-400) (FITC) (ABIN7160055)

Antigène: MAP3K7 (Mitogen-Activated Protein Kinase Kinase Kinase 7 (MAP3K7))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp MAP3K7 est conjugé à/à la FITC

Application: Veuillez nous consulter SVP

Détail du produit anti-MAP3K7 anticorps (FITC)

Épitope: AA 101-400

Fonction: MAP3K7 Antibody, FITC conjugated

Purification: Protein G purified

Pureté: >95 %

Immunogène: Recombinant Human Mitogen-activated protein kinase kinase kinase 7 protein (101-400AA)

Isotype: IgG

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur MAP3K7

Antigène: MAP3K7 (Mitogen-Activated Protein Kinase Kinase Kinase 7 (MAP3K7))

Autre désignation: MAP3K7

Sujet:

Background: Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Mediates signal transduction of TRAF6, various cytokines including interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR). Ceramides are also able to activate MAP3K7/TAK1. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade and the p38 MAPK signal transduction cascade through the phosphorylation and activation of several MAP kinase kinases like MAP2K1/MEK1, MAP2K3/MKK3, MAP2K6/MKK6 and MAP2K7/MKK7. These MAP2Ks in turn activate p38 MAPKs, c-jun N-terminal kinases (JNKs) and I-kappa-B kinase complex (IKK). Both p38 MAPK and JNK pathways control the transcription factors activator protein-1 (AP-1), while nuclear factor-kappa B is activated by IKK. MAP3K7 activates also IKBKB and MAPK8/JNK1 in response to TRAF6 signaling and mediates BMP2-induced apoptosis. In osmotic stress signaling, plays a major role in the activation of MAPK8/JNK1, but not that of NF-kappa-B. Promotes TRIM5 capsid-specific restriction activity.

Aliases: M3K7_HUMAN antibody, MAP3K 7 antibody, Map3k7 antibody, MEKK7 antibody, Mitogen activated protein kinase kinase kinase 7 antibody, Mitogen-activated protein kinase kinase kinase 7 antibody, TAK1 antibody, TGF beta activated kinase 1 antibody, TGF-beta-activated kinase 1 antibody, TGF1a antibody, Transforming growth factor beta activated kinase 1 antibody, Transforming growth factor-beta-activated kinase 1 antibody

UniProt: O43318

Pathways: Signalisation NF-kappaB, TCR Signaling, Signalisation TLR, Fc-epsilon Receptor Signaling Pathway, Activation of Innate immune Response, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Tube Formation, Toll-Like Receptors Cascades, BCR Signaling, Ubiquitin Proteasome Pathway